| 8:30 AM - 9:00 AM | Check-in and Breakfast |
| 9:00 AM - 9:45 AM | Session I: Welcome Remarks and Opening Keynote 9:00 AM
Welcome Remarks
Megan Prescott, PhD, The New York Academy of Sciences
9:15 AM
Keynote Presentation: B Cells as a Therapeutic Target in Autoimmune Diseases
Betty Diamond, PhD, Feinstein Institutes for Medical Research |
| 9:45 AM - 10:35 AM | Networking Break |
| 10:35 AM - 12:05 PM | Session II: Therapeutic Alterations in Immune Cell Composition 10:35 AM
Targeting Lymphocytes With CAR T Cells to Treat Autoimmunity
James N. Kochenderfer, MD, National Cancer Institute, National Institutes of Health
11:05 AM
Strategies to Decrease CAR-T Cell Toxicity
Christopher M. Jewell, PhD, University of Maryland
11:35 PM
Strategies to Promote Regulatory T Cell Function in Autoimmunity
Megan K. Levings, PhD, University of British Columbia |
| 12:05 PM - 1:35 PM | Networking Lunch |
| 1:35 PM - 1:55 PM | Session III: Short Talks From Submitted Abstracts 1:35 PM
Challenges in Manufacturing CAR-T Therapeutics for Autoimmune Diseases and Cancer
B. Wayne Bequette, PhD, Rensselaer Polytechnic Institute
1:45 PM
BCR-CART: A Precision CAR T Cell Platform Targeting B Cell Receptors (BCR) Selectively Eliminates Self-Reactive B Cells in Multiple Autoimmune Diseases
Ivan Cohen, PhD, University of Pennsylvania |
| 1:55 PM - 2:40 PM | Session IV: Keynote Presentation 1:55 PM
Keynote Presentation: Chimeric Receptors Broaden the Therapeutic Landscape for Autoimmune Disease
Marko Radic, PhD, University of Tennessee Health Science Center |
| 2:40 PM - 3:15 PM | Networking Break |
| 3:15 PM - 4:45 PM | Session V: Next Generation T Cell Therapies 3:15 PM
Off-the-Shelf and On-Target: How iPSC-Derived CAR T Cells Could Democratize Autoimmune Cell Therapy
Bobby Goulding, Fate Therapeutics
3:45 PM
Development and Characterization of iPSC-Derived Regulatory T cells – Towards an Allogenic Cell Therapy for the Treatment of Autoimmunity and Inflammatory Conditions
Marc Martinez Llordella, PhD, Quell Therapeutics Ltd
4:15 PM
Designing the Best CARs, Lessons from Cancer
Naomi Taylor, MD, PhD, National Cancer Institute, National Institutes of Health |
| 4:45 PM - 5:25 PM | Session VI: Panel Discussion: Opportunities and Challenges Moderator: George Zavoico, PhD, Northwest Biotherapeutics
Panelists:
Betty Diamond, PhD, The Feinstein Institutes for Medical Research
Marc Martinez Llordella, PhD, Quell Therapeutics Ltd
Bobby Goulding, PhD, Fate Therapeutics |
| 5:25 PM - 5:30 PM | Closing Remarks Megan Prescott, PhD, The New York Academy of Sciences |